ZA200107388B - 16-Hydroxyestratrienes as selective estrogens. - Google Patents
16-Hydroxyestratrienes as selective estrogens. Download PDFInfo
- Publication number
- ZA200107388B ZA200107388B ZA200107388A ZA200107388A ZA200107388B ZA 200107388 B ZA200107388 B ZA 200107388B ZA 200107388 A ZA200107388 A ZA 200107388A ZA 200107388 A ZA200107388 A ZA 200107388A ZA 200107388 B ZA200107388 B ZA 200107388B
- Authority
- ZA
- South Africa
- Prior art keywords
- diol
- triene
- estra
- chain
- fluoro
- Prior art date
Links
- 229940011871 estrogen Drugs 0.000 title description 25
- 239000000262 estrogen Substances 0.000 title description 25
- PYTMPVZFYYVDQO-UIRRPCRCSA-N (9r,10s,13r)-13-methyl-1,2,3,4,5,6,9,10,11,12-decahydrocyclopenta[a]phenanthren-16-ol Chemical class C([C@@H]12)CCCC1CC=C1[C@@H]2CC[C@@]2(C)C1=CC(O)=C2 PYTMPVZFYYVDQO-UIRRPCRCSA-N 0.000 title description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 91
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 76
- 229920006395 saturated elastomer Polymers 0.000 claims description 68
- 238000011282 treatment Methods 0.000 claims description 57
- 125000005843 halogen group Chemical group 0.000 claims description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
- 239000000126 substance Substances 0.000 claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 28
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 27
- 230000002265 prevention Effects 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- -1 heteroaryl radical Chemical class 0.000 claims description 24
- 125000003107 substituted aryl group Chemical group 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 210000000988 bone and bone Anatomy 0.000 claims description 15
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 12
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 210000004291 uterus Anatomy 0.000 claims description 10
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 8
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 125000001174 sulfone group Chemical group 0.000 claims description 8
- 150000003462 sulfoxides Chemical class 0.000 claims description 8
- 125000004434 sulfur atom Chemical group 0.000 claims description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 8
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 6
- 238000010494 dissociation reaction Methods 0.000 claims description 5
- 230000005593 dissociations Effects 0.000 claims description 5
- 238000002657 hormone replacement therapy Methods 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 208000033830 Hot Flashes Diseases 0.000 claims description 4
- 206010060800 Hot flush Diseases 0.000 claims description 4
- 206010030247 Oestrogen deficiency Diseases 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 230000001076 estrogenic effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010021639 Incontinence Diseases 0.000 claims description 3
- 206010027951 Mood swings Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000015124 ovarian disease Diseases 0.000 claims description 3
- 201000004535 ovarian dysfunction Diseases 0.000 claims description 3
- 231100000543 ovarian dysfunction Toxicity 0.000 claims description 3
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 30
- 150000003254 radicals Chemical class 0.000 claims 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 4
- 208000007984 Female Infertility Diseases 0.000 claims 4
- 206010021928 Infertility female Diseases 0.000 claims 4
- 208000007466 Male Infertility Diseases 0.000 claims 4
- RJXYZZFLBRJZSO-FATGLHCASA-N (7r,8s,9s,13r,14s,16r)-7,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16-diol Chemical compound C1C[C@]2(C)C[C@H](O)C[C@H]2[C@@H]2[C@H](C)CC3=CC(O)=CC=C3[C@H]21 RJXYZZFLBRJZSO-FATGLHCASA-N 0.000 claims 2
- LFWUNLBGZUAQFP-NPFDDYGESA-N (7r,8s,9s,13r,14s,16r)-7-fluoro-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16-diol Chemical compound C([C@H]1F)C2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1C[C@@H](O)C[C@@]1(C)CC2 LFWUNLBGZUAQFP-NPFDDYGESA-N 0.000 claims 2
- DVMAUGGKVWJBDV-COMOZRQASA-N (8s,9s,13r,14s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16-diol Chemical class C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC(O)C[C@@]1(C)CC2 DVMAUGGKVWJBDV-COMOZRQASA-N 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010022998 Irritability Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000009826 neoplastic cell growth Effects 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000022925 sleep disturbance Diseases 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- KMOZIGUQSUBLHS-VCSUWNSYSA-N (7r,8r,9s,13r,14s,16r)-13-methyl-7-phenyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-2,3,16-triol Chemical compound C1([C@@H]2CC3=CC(O)=C(O)C=C3[C@@H]3[C@@H]2[C@@H]2C[C@@H](O)C[C@]2(CC3)C)=CC=CC=C1 KMOZIGUQSUBLHS-VCSUWNSYSA-N 0.000 claims 1
- ZHQXJPFQZIPHDF-KYSZGLPYSA-N (7s,8s,9s,13r,14s,16r)-13-methyl-7-prop-1-enyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16-diol Chemical compound C1C[C@]2(C)C[C@H](O)C[C@H]2[C@@H]2[C@H](C=CC)CC3=CC(O)=CC=C3[C@H]21 ZHQXJPFQZIPHDF-KYSZGLPYSA-N 0.000 claims 1
- DVMAUGGKVWJBDV-FWEDZOCSSA-N (8r,9s,13r,14s,16r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16-diol Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@H]1[C@@H]1C[C@@H](O)C[C@@]1(C)CC2 DVMAUGGKVWJBDV-FWEDZOCSSA-N 0.000 claims 1
- VDKBOBWZCXRSID-QVMPKODKSA-N (8s,9s,13r,14s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-2,3,16-triol Chemical compound C1CC2=CC(O)=C(O)C=C2[C@@H]2[C@@H]1[C@@H]1CC(O)C[C@@]1(C)CC2 VDKBOBWZCXRSID-QVMPKODKSA-N 0.000 claims 1
- VDKBOBWZCXRSID-CVRPBIKUSA-N (8s,9s,13r,14s,16r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-2,3,16-triol Chemical compound C1CC2=CC(O)=C(O)C=C2[C@@H]2[C@@H]1[C@@H]1C[C@@H](O)C[C@@]1(C)CC2 VDKBOBWZCXRSID-CVRPBIKUSA-N 0.000 claims 1
- DVMAUGGKVWJBDV-FXXCCUJSSA-N (8s,9s,13r,14s,16r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16-diol Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1C[C@@H](O)C[C@@]1(C)CC2 DVMAUGGKVWJBDV-FXXCCUJSSA-N 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- 101000706020 Nicotiana tabacum Pathogenesis-related protein R minor form Proteins 0.000 claims 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 11
- 102000015694 estrogen receptors Human genes 0.000 description 11
- 108010038795 estrogen receptors Proteins 0.000 description 11
- 102100029951 Estrogen receptor beta Human genes 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 210000002307 prostate Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000583 progesterone congener Substances 0.000 description 5
- 238000009164 estrogen replacement therapy Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 2
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- PSOZMUMWCXLRKX-UHFFFAOYSA-N 2,4-dinitro-6-pentan-2-ylphenol Chemical compound CCCC(C)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O PSOZMUMWCXLRKX-UHFFFAOYSA-N 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 206010063408 Bladder hypertrophy Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000001395 anti-uterotrophic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000003152 gestagenic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 108091008916 nuclear estrogen receptors subtypes Proteins 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004231 tunica media Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0055—Estrane derivatives not substituted in position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19906159A DE19906159A1 (de) | 1999-02-09 | 1999-02-09 | 16-Hydroxyestratriene als selektiv wirksame Estrogene |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200107388B true ZA200107388B (en) | 2005-01-25 |
Family
ID=7897485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200107388A ZA200107388B (en) | 1999-02-09 | 2001-09-06 | 16-Hydroxyestratrienes as selective estrogens. |
Country Status (30)
Country | Link |
---|---|
EP (2) | EP1144431B1 (sh) |
JP (1) | JP2002536455A (sh) |
KR (1) | KR20010101822A (sh) |
CN (1) | CN1346364A (sh) |
AR (1) | AR034392A1 (sh) |
AT (1) | ATE313553T1 (sh) |
AU (1) | AU2909500A (sh) |
BG (1) | BG105804A (sh) |
BR (1) | BR0008076A (sh) |
CA (1) | CA2359660A1 (sh) |
CO (1) | CO5150223A1 (sh) |
CZ (1) | CZ20012843A3 (sh) |
DE (2) | DE19906159A1 (sh) |
DK (1) | DK1144431T3 (sh) |
EA (1) | EA200100828A1 (sh) |
EE (1) | EE200100412A (sh) |
ES (1) | ES2255983T3 (sh) |
HK (1) | HK1046145A1 (sh) |
HU (1) | HUP0200055A3 (sh) |
IL (1) | IL144455A0 (sh) |
MX (1) | MXPA01008065A (sh) |
NO (1) | NO20013860L (sh) |
NZ (1) | NZ513409A (sh) |
PE (1) | PE20001461A1 (sh) |
PL (1) | PL350360A1 (sh) |
PT (1) | PT1144431E (sh) |
SK (1) | SK11302001A3 (sh) |
WO (1) | WO2000047603A2 (sh) |
YU (1) | YU57201A (sh) |
ZA (1) | ZA200107388B (sh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10039199A1 (de) * | 2000-08-10 | 2002-02-21 | Schering Ag | Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen |
DE10048634A1 (de) * | 2000-09-27 | 2002-04-18 | Jenapharm Gmbh | 19-Nor-17alpha-pregna-1,3,5(10)-trien-17beta-ole mit einem 21, 16alpha-Laktonring |
DE10151365A1 (de) | 2001-10-17 | 2003-04-30 | Schering Ag | 17-Chlor-D-Homosteroide als selektive Estrogenrezeptorantagonisten |
DE10151114A1 (de) * | 2001-10-15 | 2003-04-17 | Schering Ag | 8ß-Substituierte-11ß-aryl-estra-2,3,5(10)-trienderivate |
DE10151363A1 (de) * | 2001-10-17 | 2003-05-08 | Schering Ag | Somatotrope Therapie |
US7414043B2 (en) | 2002-06-11 | 2008-08-19 | Schering Ag | 9-α-substituted estratrienes as selectively active estrogens |
DE10226326A1 (de) * | 2002-06-11 | 2004-01-15 | Schering Ag | 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene |
TWI392682B (zh) * | 2006-04-13 | 2013-04-11 | Sigma Tau Ind Farmaceuti | 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物 |
TWI389917B (zh) * | 2006-04-13 | 2013-03-21 | Sigma Tau Ind Farmaceuti | 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物 |
SE536263C2 (sv) * | 2011-12-21 | 2013-07-23 | Airqone Building Scandinavia Ab | Reningsanordning för gasmedium innefattande medel för kontrollerad tillförsel av joniserad luft |
EP3500265B1 (en) * | 2016-08-22 | 2023-10-04 | Or-Genix Therapeutics, Inc. | Estrogen receptor beta selective ligands |
WO2019041078A1 (en) * | 2017-08-28 | 2019-03-07 | Zhejiang Jiachi Pharmaceutical Development Ltd. | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES |
CN113056473A (zh) * | 2018-09-07 | 2021-06-29 | 达特茅斯学院托管理事会 | C19支架和甾体及其使用和制造方法 |
CN115154474A (zh) * | 2021-04-01 | 2022-10-11 | 中国人民解放军总医院 | 一种环菠萝蜜烷型三萜皂苷化合物在制备t细胞免疫抑制剂中的应用 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3079408A (en) * | 1963-02-26 | Ig-bisoxygenated iy-haloestra- | ||
US3103524A (en) * | 1963-09-10 | Ratetraene- | ||
GB823955A (en) * | 1955-09-01 | 1959-11-18 | Nepera Chemical Co Inc | Improvements in steroid compounds and method for manufacture of same |
GB804789A (en) * | 1956-02-06 | 1958-11-26 | Searle & Co | 16-alkylestratriene-3,16,17-triols and derivatives thereof |
US2779773A (en) * | 1956-05-23 | 1957-01-29 | Nepera Chemical Co Inc | Steroid 3, 16alpha-diols and process |
US3166473A (en) * | 1962-04-12 | 1965-01-19 | Mochida Pharm Co Ltd | New esters of 1, 3, 5-estratriene-3, 16, 17-triol and novel pharmaceutical compositions containing new esters of 1, 3, 5-estratriene-3, 16, 17-triol and esters of 1, 3, 5-estratriene-3, 16, 17-triol |
NL124324C (sh) * | 1964-01-24 | |||
FR4339M (sh) * | 1965-03-29 | 1966-08-08 | ||
FR5099M (sh) * | 1966-01-12 | 1967-05-22 | ||
US3449383A (en) * | 1967-02-16 | 1969-06-10 | Searle & Co | 17-oxygenated estra-1,3,5(10)-triene-3,11beta,16-triols,ethers and esters thereof |
US3470159A (en) * | 1967-07-13 | 1969-09-30 | American Home Prod | Estra-1,3,5(10),7-tetraenes and process of preparation |
CH537916A (de) * | 1969-02-27 | 1973-06-15 | Ciba Geigy Ag | Verfahren zur Herstellung eines neuen Östratriols |
CH538460A (de) * | 1969-02-27 | 1973-06-30 | Ciba Geigy Ag | Verfahren zur Herstellung eines neuen hochwirksamen Östratriols |
GB1235642A (en) * | 1969-02-27 | 1971-06-16 | Ciba Geigy | A new oestratriol and a process for its manufacture |
FR2034569B1 (sh) * | 1969-02-27 | 1973-07-13 | Ciba Geigy Ag | |
US3600705A (en) * | 1969-02-27 | 1971-08-17 | Gen Electric | Highly efficient subcritically doped electron-transfer effect devices |
US3622670A (en) * | 1969-08-22 | 1971-11-23 | American Home Prod | Method of inducing ovulation |
IL38806A0 (en) * | 1971-03-05 | 1972-04-27 | Ciba Geigy Ag | Pharmaceutical compositions comprising estrogens and anthracene derivatives |
US3766224A (en) * | 1971-06-03 | 1973-10-16 | Sandoz Ag | 15-methyl-substituted steroids |
US3946052A (en) * | 1975-06-16 | 1976-03-23 | Stanford Research Institute | 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity |
JPS5265259A (en) * | 1975-11-27 | 1977-05-30 | Takeda Chem Ind Ltd | Synthesis of 16beta-alkylestradiol or its 17-esters |
NL7613248A (nl) * | 1976-11-26 | 1978-05-30 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroid- esters. |
DD145919B1 (de) * | 1978-06-28 | 1982-06-30 | Kurt Ponsold | Verfahren zur herstellung von 14,1 -methylenderivaten der oestranreihe |
SE8305596D0 (sv) * | 1983-10-12 | 1983-10-12 | Leo Ab | A selective acylation method |
DE3510555A1 (de) * | 1985-03-21 | 1986-09-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | Estriolester |
US4705783A (en) * | 1985-06-25 | 1987-11-10 | Sri International | 9α, 11β-substituted and 11β-substituted estranes |
HU208150B (en) * | 1988-10-31 | 1993-08-30 | Endorecherche Inc | Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives |
SU1761760A1 (ru) * | 1990-07-02 | 1992-09-15 | Всесоюзный Эндокринологический Научный Центр Амн Ссср | Способ получени 11-нитратов 9 @ , 11 @ -диоксистероидов |
DE4239946C2 (de) * | 1992-11-27 | 2001-09-13 | Jenapharm Gmbh | Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung |
DE4322186A1 (de) * | 1993-07-03 | 1995-01-12 | Jenapharm Gmbh | Oral estrogen wirksame Ester des 14alpha, 15alpha-Methylen-estradiols |
DE4326240A1 (de) * | 1993-08-02 | 1995-02-09 | Schering Ag | 15,15-Dialkyl-substituierte Derivate des Estradiols |
US5554603A (en) * | 1993-09-17 | 1996-09-10 | The United States Of America As Represented By The Department Of Health And Human Services | Orally active derivatives of 1,3,5(10)-estratriene |
DE4338314C1 (de) * | 1993-11-10 | 1995-03-30 | Jenapharm Gmbh | Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen |
SE9502921D0 (sv) * | 1995-08-23 | 1995-08-23 | Astra Ab | New compounds |
DE19635525A1 (de) * | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
DE19815060A1 (de) * | 1998-04-03 | 1999-10-14 | Jenapharm Gmbh | Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie |
-
1999
- 1999-02-09 DE DE19906159A patent/DE19906159A1/de not_active Withdrawn
-
2000
- 2000-02-08 PE PE2000000093A patent/PE20001461A1/es not_active Application Discontinuation
- 2000-02-08 CO CO00007990A patent/CO5150223A1/es unknown
- 2000-02-09 CN CN00803613A patent/CN1346364A/zh active Pending
- 2000-02-09 SK SK1130-2001A patent/SK11302001A3/sk unknown
- 2000-02-09 CZ CZ20012843A patent/CZ20012843A3/cs unknown
- 2000-02-09 ES ES00907539T patent/ES2255983T3/es not_active Expired - Lifetime
- 2000-02-09 YU YU57201A patent/YU57201A/sh unknown
- 2000-02-09 EP EP00907539A patent/EP1144431B1/de not_active Expired - Lifetime
- 2000-02-09 CA CA002359660A patent/CA2359660A1/en not_active Abandoned
- 2000-02-09 AT AT00907539T patent/ATE313553T1/de not_active IP Right Cessation
- 2000-02-09 HU HU0200055A patent/HUP0200055A3/hu unknown
- 2000-02-09 EE EEP200100412A patent/EE200100412A/xx unknown
- 2000-02-09 DE DE50011908T patent/DE50011908D1/de not_active Expired - Fee Related
- 2000-02-09 JP JP2000598520A patent/JP2002536455A/ja active Pending
- 2000-02-09 MX MXPA01008065A patent/MXPA01008065A/es unknown
- 2000-02-09 KR KR1020017009989A patent/KR20010101822A/ko not_active Application Discontinuation
- 2000-02-09 DK DK00907539T patent/DK1144431T3/da active
- 2000-02-09 WO PCT/EP2000/001073 patent/WO2000047603A2/de active IP Right Grant
- 2000-02-09 EA EA200100828A patent/EA200100828A1/ru unknown
- 2000-02-09 EP EP05075149A patent/EP1580192A2/de not_active Withdrawn
- 2000-02-09 AU AU29095/00A patent/AU2909500A/en not_active Abandoned
- 2000-02-09 AR ARP000100553A patent/AR034392A1/es not_active Application Discontinuation
- 2000-02-09 PL PL00350360A patent/PL350360A1/xx not_active Application Discontinuation
- 2000-02-09 PT PT00907539T patent/PT1144431E/pt unknown
- 2000-02-09 IL IL14445500A patent/IL144455A0/xx unknown
- 2000-02-09 NZ NZ513409A patent/NZ513409A/xx unknown
- 2000-02-09 BR BR0008076-4A patent/BR0008076A/pt not_active IP Right Cessation
-
2001
- 2001-08-08 NO NO20013860A patent/NO20013860L/no not_active Application Discontinuation
- 2001-08-09 BG BG105804A patent/BG105804A/xx unknown
- 2001-09-06 ZA ZA200107388A patent/ZA200107388B/en unknown
-
2002
- 2002-10-17 HK HK02107553.2A patent/HK1046145A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7378404B2 (en) | 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens | |
US6958327B1 (en) | 18 Norsteroids as selectively active estrogens | |
ZA200107388B (en) | 16-Hydroxyestratrienes as selective estrogens. | |
US20080132476A1 (en) | Substituted estratrienes as selectively active estrogens | |
WO2000063228A1 (en) | Ent-steroids as selectively active estrogens | |
ZA200500217B (en) | 9-Alpha-substituted estratienes as selectively active estrogen | |
US20060270845A1 (en) | 16-Hydroxyestratrienes as selectively active estrogens | |
ES2286042T3 (es) | 18-nor-esteroides como estrogenos eficaces selectivamente. | |
ZA200209149B (en) | 8ß-hydrocarbyl-substituted estratrienes for use as selective estrogens | |
EP2176282B1 (en) | 8-beta-substituted 16.alpha.-fluoro-estratrienes as selectively active estrogens | |
US20050282791A1 (en) | 18-nor steroids as selectively active estrogens | |
AU2004201405A1 (en) | Ent-Steroids as selectively active estrogens |